How to appeal a UnitedHealthcare prostate cancer denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

UnitedHealthcare-specific note: UHC's parent UnitedHealth Group owns Optum (PBM Optum Rx) and Surest. Surest plans have different cost-sharing rules. State complaints flow to state insurance department + DOL/EBSA for self-funded.

What UnitedHealthcare's policy requires for prostate cancer

Cited policy: OptumRx Pluvicto (Lutetium Lu 177 vipivotide tetraxetan) Prior Authorization

PSMA-positive mCRPC confirmed on FDA-approved PSMA-PET (Pylarify / Locametz / Posluma) with VISION SUV criteria. Per Mar 28, 2025 label expansion: prior progression on ≥1 ARSI (abiraterone / enzalutamide / apalutamide / darolutamide); taxane chemo no longer required when chemo can be delayed (PSMAfore population). Adequate marrow (ANC ≥1.5, plt ≥100, Hgb ≥9), eGFR ≥30, ALT/AST ≤3x ULN, ECOG 0-2. Up to 6 cycles 7.4 GBq IV q6wk. Administered at authorized radioligand center.

How UnitedHealthcare denies prostate cancer — and how to counter it

Where UnitedHealthcare pushes back: 1) Must fail multiple chemo lines first; 2) PSMA-PET unnecessary, use bone scan; 3) Insufficient PSMA expression documentation.

Counter-arguments that hold up: VISION NEJM 2021 Sartor — Pluvicto + SOC OS HR 0.62 (15.3 vs 11.3 mo) post-ARSI + post-taxane. PSMAfore Lancet 2024 — pre-chemo rPFS HR 0.41 (59% reduction) basis for FDA Mar 28, 2025 label expansion. PSMA-PET REQUIRED for Pluvicto eligibility (cannot determine PSMA-positivity from CT/bone scan). NCCN Prostate v1.2025 Category 1 for PSMA+ mCRPC post-ARSI. Submit PSMA-PET report with SUVmax + lesion count meeting VISION criteria (SUVmean ≥10 dominant lesion, no PSMA-negative dominant lesions).

What UnitedHealthcare typically denies for prostate cancer

Across UnitedHealthcare's commercial and Medicare books, denials cluster around a small number of patterns. For prostate cancer, expect:

• GLP-1 weight-loss exclusion
• Out-of-network reduction citing UCR
• Step therapy on biologics
• Prior auth denied for advanced imaging
• Quantity limits on specialty drugs

Treatments most often denied in this category

These are the prostate cancer treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Pluvicto (177Lu-PSMA-617)
• Xofigo (radium-223)
• Xtandi (enzalutamide)
• Erleada (apalutamide)
• Nubeqa (darolutamide)
• Zytiga (abiraterone)

How to submit the appeal to UnitedHealthcare

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document UnitedHealthcare cited in the denial.
3. File the appeal through UnitedHealthcare's portal (members: https://www.myuhc.com ; providers: https://www.uhcprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MN, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See UnitedHealthcare's prior-authorization criteria by drug: UnitedHealthcare PA criteria on ApprovalHelp.